医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Scanditronic becomes Ascom

2014年12月16日 AM10:00
このエントリーをはてなブックマークに追加


 

KUALA LUMPUR, Malaysia & GOTHENBURG, Sweden

Ascom, a global provider of mission-critical communications systems, recently acquired Scanditronic, a distributor of Ascom’s products in Malaysia and the South East Asia region.

As of November 1st Scanditronic has changed its legal entity name to Ascom (Malaysia) Sdn. Bhd. and will be running under the Ascom Wireless Solutions division which is headquartered in Gothenburg, Sweden.

Ascom (Malaysia) will lead all of the Ascom Wireless Solutions operations in the South East Asian region, delivering mobility, nurse call and middleware solutions for the healthcare, retail, hospitality and shipping segments. The acquisition will further strengthen the support to existing customers, and enhances Ascom’s presence in South East Asia.

For more information visit www.ascom.com/ws

ABOUT ASCOM WIRELESS SOLUTIONS

Ascom Wireless Solutions (www.ascom.com/ws) is a leading provider of on-site wireless communications for key segments such as hospitals, elderly care, independent living, manufacturing industries, secure establishments, retail and hotels. More than 75,000 systems are installed at major companies all over the world. The company offers a broad range of voice and professional messaging solutions, creating value for customers by supporting and optimizing their Mission-Critical processes. The solutions are based on VoWiFi, IP-DECT, nurse call and paging technologies, smartly integrated into existing enterprise systems. The company has subsidiaries in 13 countries and 1,200 employees worldwide. Founded in 1955 and based in Göteborg, Sweden, Ascom Wireless Solutions is part of the Ascom Group, listed on the Swiss Stock Exchange.

CONTACT

Ascom Malaysia
Hans Tysk, Managing Director,
Tel: +60 342 52
47 49
Email: Hans.Tysk@ascom-ws.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Cyclica and IMPACT Therapeutics Team Up to Advance Differentiated Anti-cancer Drug Development
  • Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries
  • AnHeart Therapeutics Announces Formation of Scientific Advisory Board
  • Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
  • Celltrion用于治疗COVID-19的单克隆抗体瑞丹维单抗(CT-P59)成为韩国食品药品安全部(MFDS)首个核准用于治疗COVID-19的药物